Peking University Cancer Hospital & Institute

This study tests whether matching drug combinations to a patient's tumor genetics can help when standard immunotherapy stops working. About 90 people with advanced esophageal cancer will get one of three treatment pairs based on their cancer's molecular profile. The goal is to se…

This study looks at whether immunotherapy can shrink certain gastrointestinal cancers (like colorectal or stomach cancer) enough that some patients may not need major surgery. People whose tumors have specific genetic features (MSI-H/dMMR or POLE mutation) and who respond well to…

This study looks at whether people with certain genetic types of gastrointestinal cancers (stomach, colorectal, or anal) can safely avoid major surgery after immunotherapy. Instead of removing the organ, doctors will monitor closely or do smaller procedures to remove any remainin…

This phase II trial is testing whether the targeted therapy firmonertinib, taken as a pill for 8 to 16 weeks before surgery, can shrink tumors in people with stage II-IIIB EGFR-mutated lung adenocarcinoma. About 60 participants will receive the drug and then undergo surgery to re…

This phase 2 trial tests a new immunotherapy drug called iparomlimab tolvorlimab (QL1706) in 30 people with a specific type of locally advanced stomach cancer (MSI-H/dMMR). The drug is given before and after surgery to see if it can eliminate the tumor. The main goal is to see ho…

This study tests whether starting abemaciclib at a lower dose and gradually increasing it can reduce early side effects like diarrhea and fatigue in people with high-risk HR+/HER2- breast cancer. The goal is to help more patients stay on their full treatment plan. About 86 partic…

This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa…

This study tests whether a special PET scan (HER2-PET) can help doctors personalize treatment for early-stage HER2-positive breast cancer. After two cycles of standard therapy, the scan results will determine if patients need stronger or milder treatment. The goal is to improve t…

This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help control HER2-positive advanced breast cancer longer. About 42 adults with advanced disease will receive this combination as maintenance therapy after initial treatment. The ma…

This study compares a new drug, SHR-A1811, with a standard combination therapy (pyrotinib plus capecitabine) in 100 adults with advanced HER2-positive breast cancer that did not respond to the first-line treatment trastuzumab. The goal is to see which approach better delays cance…

This phase 2 trial is testing a new approach for people with stage II-III rectal cancer. It combines short-course radiotherapy that spares the tumor-draining lymph nodes with a PD-1 inhibitor (a type of immunotherapy). The goal is to see if this combination can lead to a complete…

This Phase 2 trial tests whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy, followed by maintenance adebrelimab, can help control limited-stage small cell lung cancer. About 76 adults aged 18-75 with untreated localized disease will be enrolled. The …

This phase 2 trial tests whether adding radiotherapy and two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy and bevacizumab can improve outcomes for people with a specific type of metastatic rectal cancer (RAS-mutant/MSS). About 106 participants will …

This study looks at people with limited-stage small cell lung cancer whose disease is under control after chemoradiation. A special blood test (MRD) checks for leftover cancer signals. Those with positive results get a combination of immunotherapy and anti-angiogenic drugs to try…

This study tests a standardized care plan for esophageal fistula, a severe complication of advanced esophageal cancer where a hole forms between the esophagus and windpipe or chest. The plan includes sealing the hole with stents, antibiotics, nutrition support, and further cancer…

This study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …

This Phase 2 trial tests the immunotherapy drug ivonescimab, alone or with chemotherapy, before and after surgery for people with stage II-IIIB non-small cell lung cancer that can be removed. The goal is to see if tailoring treatment based on PD-L1 levels can reduce toxicity whil…

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy can help people with limited-stage small-cell lung cancer. About 30 participants will receive the combination, followed by maintenance adebrelimab for up to 2 years. The …

This study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…

This study tests a robotic bronchoscope to inject a dye near small lung nodules before they are removed surgically. The dye helps surgeons see the nodule during operation, making removal more accurate. Fifty patients with hard-to-find nodules will be enrolled, and researchers wil…

This study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrin…

This phase 3 trial tests whether a combination of two drugs, vorolanib and everolimus, can help people with advanced kidney cancer whose disease has worsened after immunotherapy. About 116 participants will be randomly assigned to receive either the combo or the standard drug sun…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study will compare two different PET/MRI scans to see which one is better at finding lymph node metastases in people with middle to high rectal cancer. Thirty participants will receive both types of scans before surgery. The goal is to see if the newer tracer, [68Ga]Ga-CTR-F…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study tests whether taking your own gut bacteria (autologous probiotics) can reduce bowel problems after ileostomy closure in rectal cancer patients. Forty adults who had rectal cancer surgery with a temporary ileostomy will receive capsules containing their own lactobacillu…

This study tests if a traditional Chinese medicine hand and foot bath can help control nerve pain and numbness caused by chemotherapy in breast cancer patients. About 78 adults will either receive the herbal bath or a standard vitamin treatment. The goal is to see which approach …

This study will follow 255 people with esophageal cancer to understand how the disease changes over time. Researchers will use advanced tests like genetic analysis, imaging, and immune profiling. The goal is to improve how doctors predict cancer progression and response to treatm…